Syndax Pharmaceuticals (NASDAQ:SNDX) posted its earnings results on Thursday. The company reported ($0.41) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.48) by $0.07, Fidelity Earnings reports. Syndax Pharmaceuticals had a negative return on equity of 108.44% and a negative net margin of 4,310.68%. The firm had revenue of $0.38 million for the quarter, compared to the consensus estimate of $0.38 million.
Shares of Syndax Pharmaceuticals stock traded up $0.01 during midday trading on Friday, hitting $6.97. The company had a trading volume of 186,700 shares, compared to its average volume of 163,226. The company has a 50 day moving average of $7.05 and a 200 day moving average of $8.12. The stock has a market capitalization of $194.57 million, a P/E ratio of -2.39 and a beta of 2.39. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.90 and a current ratio of 4.90. Syndax Pharmaceuticals has a 52-week low of $3.39 and a 52-week high of $11.11.
SNDX has been the topic of a number of research analyst reports. ValuEngine downgraded Syndax Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Tuesday, October 29th. HC Wainwright reiterated a “buy” rating on shares of Syndax Pharmaceuticals in a report on Tuesday, July 16th. Nomura reiterated a “buy” rating and set a $16.00 target price on shares of Syndax Pharmaceuticals in a report on Sunday, August 11th. Cowen reiterated a “buy” rating on shares of Syndax Pharmaceuticals in a report on Friday. Finally, BidaskClub downgraded Syndax Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday, August 24th. One research analyst has rated the stock with a sell rating, two have given a hold rating and seven have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $12.96.
Syndax Pharmaceuticals Company Profile
Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. The company's lead product candidates include entinostat, which is in Phase III clinical trials for the treatment of advanced hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative (HER2-) breast cancer; and SNDX-5613 inhibitor that targets the binding interaction of Menin with mixed lineage leukemia-rearranged and acute myeloid leukemia with a mutated nucleophosmin 1.
See Also: How to Invest in Marijuana Stocks
Receive News & Ratings for Syndax Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syndax Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.